Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Confirmed Link Between Chronic Infection And Immune-System Protein
The reason deadly infections like human immunodeficiency virus (HIV) and hepatitis C never go away is because these viruses disarm the body"s defense system. Researchers at the University of Alabama at Birmingham (UAB) have discovered that a key immunity protein must be present for this defense system to have a chance against chronic infection.

Genentech And Biogen Idec Submit Applications To The FDA For Rituxan For Most Common Type Of Adult Leukemia
Genentech, Inc. and Biogen Idec (Nasdaq:BIIB) announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan® (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months.
News of the day
Alzheimer's Prediction And Diagnosis May Be Improved By Brain Imaging And Proteins In Spinal Fluid
Changes in the brain measured with MRI and PET scans, combined with memory tests and detection of risk proteins in body fluids, may lead to earlier and more accurate diagnosis of Alzheimer"s, according to new research reported at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna.
Diagnostics

Study Looks At Efficacy, Cardiovascular Risks Of Two HIV Treatments

Patients taking Boehringer Ingelheim"s HIV drug Viramune have a lower risk of developing cardiovascular disease than those taking Bristol-Myers Squibb"s treatment, Reyataz, according to a study released on Monday at the 5th International AIDS Society conference in Cape Town, South Africa, Reuters reports. "The drug trial, involving 569 participants, yielded that Viramune, while being as effective at suppressing HIV as Bristol Myers" blockbuster Reyataz, had a more favourable effect on patients" cardiovascular risks, as measured by certain blood lipids," the article states. The study found that "Viramune-treated patients ò€¦ had more than twice the level of HDL cholesterol, known as "good cholesterol" for its benefitial effect on blood vessels, than those on Reyataz, Boehringer said in a statement," Reuters reports. The article adds that advances in antiretroviral drugs have helped make HIV a "treatable chronic condition," and "as a result, patients are growing older, bringing other symptoms of an HIV infection, such as cardiovascular diseases, to the fore" (Burger, Reuters, 7/20). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009